Parallax Volatility Advisers
APLS

Parallax Volatility Advisers’s Apellis Pharmaceuticals APLS Stock Holding History

Parallax Volatility Advisers’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,000
Closed -$519K – 1590
2025
Q2 		$519K Hold
30,000
– – ﹤0.01% 1179
2025
Q1 		$656K Buy
+30,000
New +$829K ﹤0.01% 1143
2024
Q1 		– Sell
-100
Closed -$5.99K – 1807
2023
Q4 		$5.99K Buy
+100
New +$5.07K ﹤0.01% 2040
2023
Q2 		– Sell
-400
Closed -$26.4K – 2368
2023
Q1 		$26.4K Sell
400
-74,600
-99% -$4.3M ﹤0.01% 2293
2022
Q4 		$3.88M Buy
+75,000
New +$3.98M 0.01% 1130
2020
Q2 		– Sell
-24,500
Closed -$656K – 2688
2020
Q1 		$656K Buy
24,500
+12,000
+96% +$426K ﹤0.01% 1619
2019
Q4 		$383K Buy
+12,500
New +$346K ﹤0.01% 1831

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Parallax Volatility Advisers's APLS Position: Q3 2025 in Review

Parallax Volatility Advisers sold out of Apellis Pharmaceuticals (APLS) in Q3 2025, closing a stake of 24,443 shares — an estimated $570K sold.

Parallax Volatility Advisers first reported a position in APLS in Q4 2017 and held it in 12 quarters. The position peaked at $5.27M in Q3 2022. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

  • Parallax Volatility Advisers reported no remaining Apellis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 24,443 Apellis Pharmaceuticals shares in Q3 2025, an estimated $570K.
  • Parallax Volatility Advisers first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 12 quarters.
  • Parallax Volatility Advisers's Apellis Pharmaceuticals position peaked at $5.27M in Q3 2022.
  • 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Parallax Volatility Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.